Cargando…
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). METHODS: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamyci...
Ejemplares similares
-
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
por: Schnitzbauer, Andreas A, et al.
Publicado: (2010) -
Hepatocellular carcinoma progression during bridging before liver transplantation
por: Renner, P, et al.
Publicado: (2021) -
Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
por: Obed, Aiman, et al.
Publicado: (2007) -
EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients
por: Wöhl, D. S., et al.
Publicado: (2023) -
Learning About Gene Regulatory Networks From Gene Deletion Experiments
por: Schlitt, Thomas, et al.
Publicado: (2002)